Green Tea Catechin-Based Complex Micelles Combined with Doxorubicin to Overcome Cardiotoxicity and Multidrug Resistance

Chemotherapy for cancer treatment has been demonstrated to cause some side effects on healthy tissues and multidrug resistance of the tumor cells, which greatly limits therapeutic efficacy. To address these limitations and achieve better therapeutic efficacy, combination therapy based on nanoparticle platforms provides a promising approach through delivering different agents simultaneously to the same destination with synergistic effect. In this study, a novel green tea catechin-based polyion complex (PIC) micelle loaded with doxorubicin (DOX) and (-)-Epigallocatechin-3-O-gallate (EGCG) was constructed through electrostatic interaction and phenylboronic acid-catechol interaction between poly(ethylene glycol)-block-poly(lysine-co-lysine-phenylboronic acid) (PEG-PLys/PBA) and EGCG. DOX was co-loaded in the PIC micelles through π-π stacking interaction with EGCG. The phenylboronic acid-catechol interaction endowed the PIC micelles with high stability under physiological condition. Moreover, acid cleavability of phenylboronic acid-catechol interaction in the micelle core has significant benefits for delivering EGCG and DOX to same destination with synergistic effects. In addition, benefiting from the oxygen free radicals scavenging activity of EGCG, combination therapy with EGCG and DOX in the micelle core could protect the cardiomyocytes from DOX-mediated cardiotoxicity according to the histopathologic analysis of hearts. Attributed to modulation of EGCG on P-glycoprotein (P-gp) activity, this kind of PIC micelles could effectively reverse multidrug resistance of cancer cells. These results suggested that EGCG based PIC micelles could effectively overcome DOX induced cardiotoxicity and multidrug resistance.

[1]  J. Robert,et al.  Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells. , 1995, European journal of cancer.

[2]  Gow-Chin Yen,et al.  Antioxidant activity of various tea extracts in relation to their antimutagenicity , 1995 .

[3]  E. El-demerdash,et al.  Epigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: A mechanistic study. , 2015, Biochemical pharmacology.

[4]  Hua Wei,et al.  Design and development of polymeric micelles with cleavable links for intracellular drug delivery , 2013 .

[5]  Akira Matsumoto,et al.  A phenylboronate-functionalized polyion complex micelle for ATP-triggered release of siRNA. , 2012, Angewandte Chemie.

[6]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[7]  S. Nie,et al.  A major green tea component, (-)-epigallocatechin-3-gallate, ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal rats. , 2010, Journal of agricultural and food chemistry.

[8]  Rui-sheng Li,et al.  Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[9]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[10]  J. Zasadzinski,et al.  Plasmonic Nanobubbles Enhance Efficacy and Selectivity of Chemotherapy Against Drug‐Resistant Cancer Cells , 2012, Advanced materials.

[11]  J. M. Ford,et al.  Pharmacology of drugs that alter multidrug resistance in cancer. , 1990, Pharmacological reviews.

[12]  Xuesi Chen,et al.  A pH-sensitive charge-conversion system for doxorubicin delivery. , 2013, Acta biomaterialia.

[13]  G. Hortobagyi,et al.  Anthracyclines in the Treatment of Cancer , 2012, Drugs.

[14]  N. Uskent,et al.  Prevention of doxorubicin induced cardiotoxicity by catechin. , 1996, Cancer letters.

[15]  Youqing Shen,et al.  Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers , 2010 .

[16]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[17]  B I Sikic,et al.  Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. , 1985, Cancer research.

[18]  A. Marcus,et al.  uPAR-targeted Optical Imaging Contrasts as Theranostic Agents for Tumor Margin Detection , 2013, Theranostics.

[19]  T. Miller,et al.  Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. , 1991, Journal of the National Cancer Institute.

[20]  Nicholas A Peppas,et al.  Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. , 2012, Nano today.

[21]  Binghe Wang,et al.  A detailed examination of boronic acid–diol complexation , 2002 .

[22]  Xin Wang,et al.  Cancer prevention by tea: animal studies, molecular mechanisms and human relevance , 2009, Nature Reviews Cancer.

[23]  V. Torchilin,et al.  P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. , 2012, Nanomedicine.

[24]  Yingli An,et al.  pH/sugar dual responsive core-cross-linked PIC micelles for enhanced intracellular protein delivery. , 2013, Biomacromolecules.

[25]  G. Hortobagyi,et al.  Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer , 2002, Cancer Chemotherapy and Pharmacology.

[26]  Xuesi Chen,et al.  Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects. , 2014, Acta biomaterialia.

[27]  R. Béliveau,et al.  Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. , 2002, Biochimica et biophysica acta.

[28]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[29]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  Jin-Zhi Du,et al.  Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. , 2011, Journal of the American Chemical Society.

[31]  Crispin R Dass,et al.  Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems , 2013, The Journal of pharmacy and pharmacology.

[32]  M. Dietel,et al.  Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. , 1992, Biochemical pharmacology.

[33]  W. Daly,et al.  The preparation of N-carboxyanhydrides of α-amino acids using bis(trichloromethyl)carbonate , 1988 .

[34]  N. Nishiyama,et al.  Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery. , 2009, Biomacromolecules.

[35]  Linqi Shi,et al.  A surface-adaptive nanocarrier to prolong circulation time and enhance cellular uptake. , 2015, Chemical communications.

[36]  Linqi Shi,et al.  Self-regulated multifunctional collaboration of targeted nanocarriers for enhanced tumor therapy. , 2014, Biomacromolecules.

[37]  Qiang Zhang,et al.  In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft. , 2004, Cancer letters.

[38]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[39]  Zhen Gu,et al.  Gel–Liposome‐Mediated Co‐Delivery of Anticancer Membrane‐Associated Proteins and Small‐Molecule Drugs for Enhanced Therapeutic Efficacy , 2014 .

[40]  Hak Soo Choi,et al.  Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy , 2014, Nature nanotechnology.

[41]  A. Zhu,et al.  Study of tea polyphenol as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent). , 2001, Nuclear medicine and biology.

[42]  Young-Jin Kim,et al.  Superoxide anion scavenging and xanthine oxidase inhibition of (+)-catechin-aldehyde polycondensates. Amplification of the antioxidant property of (+)-catechin by polycondensation with aldehydes. , 2004, Biomacromolecules.

[43]  R. Olson,et al.  Doxorubicin cardiotoxicity: analysis of prevailing hypotheses , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  Mohd Fahad Ullah,et al.  Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. , 2008, Asian Pacific journal of cancer prevention : APJCP.

[45]  H. Tapiero,et al.  Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. , 1986, Cancer drug delivery.

[46]  E. Skrzypczak‐Jankun,et al.  Why drinking green tea could prevent cancer , 1997, Nature.

[47]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[48]  Norman Honbo,et al.  Doxorubicin Cardiomyopathy , 2009, Cardiology.

[49]  J. Bennett,et al.  Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. , 2009, Free radical biology & medicine.

[50]  Liangfang Zhang,et al.  Nanoparticle-assisted combination therapies for effective cancer treatment. , 2010, Therapeutic delivery.

[51]  Chi-Tang Ho,et al.  Stability of tea polyphenol (-)-epigallocatechin-3-gallate and formation of dimers and epimers under common experimental conditions. , 2005, Journal of agricultural and food chemistry.

[52]  A. Tang,et al.  Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. , 2010, International journal of oncology.

[53]  J. Kreuter,et al.  Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. , 2008, Toxicology letters.

[54]  Qin Chen,et al.  Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. , 2012, Biomaterials.

[55]  K. Kataoka,et al.  Block copolymer micelles for drug delivery: design, characterization and biological significance. , 2001, Advanced drug delivery reviews.

[56]  Xiaogang Pan,et al.  Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[57]  Yinan Zhong,et al.  Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. , 2014, Biomacromolecules.

[58]  R. Kothari,et al.  Macrocyclic Copper ( II ) Complexes : Superoxide Scavenging Activity , Structural Studies and Cytotoxicity Evaluation , 2014 .

[59]  T. Fojo,et al.  Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. , 2004, Current drug targets.